Global Molecular Diagnostics in Infectious Disease Testing Market 2020 by Company, Regions, Type and Application, Forecast to 2025

Table of Contents

1 Molecular Diagnostics in Infectious Disease Testing Market Overview

• 1.1 Product Overview and Scope of Molecular Diagnostics in Infectious Disease Testing
• 1.2 Classification of Molecular Diagnostics in Infectious Disease Testing by Type
  • 1.2.1 Global Molecular Diagnostics in Infectious Disease Testing Revenue by Type: 2015 VS 2019 VS 2025
  • 1.2.2 Global Molecular Diagnostics in Infectious Disease Testing Revenue Market Share by Type in 2019
  • 1.2.3 Polymerase Chain Reaction (PCR)
  • 1.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 1.2.5 Microarrays
  • 1.2.6 Next-Generation Sequencing (NGS)
  • 1.2.7 Hybridization
  • 1.2.8 Others
• 1.3 Global Molecular Diagnostics in Infectious Disease Testing Market by Application
  • 1.3.1 Overview: Global Molecular Diagnostics in Infectious Disease Testing Revenue by Application: 2015 VS 2019 VS 2025
  • 1.3.2 Hospitals
  • 1.3.3 Clinics
  • 1.3.4 Academic Institutes
  • 1.3.5 Laboratories
  • 1.3.6 Others
• 1.4 Global Molecular Diagnostics in Infectious Disease Testing Market by Regions
  • 1.4.1 Global Molecular Diagnostics in Infectious Disease Testing Market Size by Regions: 2015 VS 2019 VS 2025
  • 1.4.2 Global Market Size of Molecular Diagnostics in Infectious Disease Testing (2015-2025)
  • 1.4.3 North America (USA, Canada and Mexico) Molecular Diagnostics in Infectious Disease Testing Status and Prospect (2015-2025)
  • 1.4.4 Europe (Germany, France, UK, Russia and Italy) Molecular Diagnostics in Infectious Disease Testing Status and Prospect (2015-2025)
  • 1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Molecular Diagnostics in Infectious Disease Testing Status and Prospect (2015-2025)
  • 1.4.6 South America (Brazil, Argentina, Colombia) Molecular Diagnostics in Infectious Disease Testing Status and Prospect (2015-2025)
  • 1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Molecular Diagnostics in Infectious Disease Testing Status and Prospect (2015-2025)

2 Company Profiles

• 2.1 Abbott
  • 2.1.1 Abbott Details
  • 2.1.2 Abbott Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.1.3 Abbott SWOT Analysis
  • 2.1.4 Abbott Product and Services
  • 2.1.5 Abbott Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.2 Luminex
  • 2.2.1 Luminex Details
  • 2.2.2 Luminex Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.2.3 Luminex SWOT Analysis
  • 2.2.4 Luminex Product and Services
  • 2.2.5 Luminex Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.3 Thermo Fisher Scientific
  • 2.3.1 Thermo Fisher Scientific Details
  • 2.3.2 Thermo Fisher Scientific Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.3.3 Thermo Fisher Scientific SWOT Analysis
  • 2.3.4 Thermo Fisher Scientific Product and Services
  • 2.3.5 Thermo Fisher Scientific Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.4 BD
  • 2.4.1 BD Details
  • 2.4.2 BD Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.4.3 BD SWOT Analysis
  • 2.4.4 BD Product and Services
  • 2.4.5 BD Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.5 Veridex
  • 2.5.1 Veridex Details
  • 2.5.2 Veridex Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.5.3 Veridex SWOT Analysis
  • 2.5.4 Veridex Product and Services
  • 2.5.5 Veridex Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.6 BioMerieux
  • 2.6.1 BioMerieux Details
  • 2.6.2 BioMerieux Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.6.3 BioMerieux SWOT Analysis
  • 2.6.4 BioMerieux Product and Services
  • 2.6.5 BioMerieux Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.7 Qiagen
  • 2.7.1 Qiagen Details
  • 2.7.2 Qiagen Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.7.3 Qiagen SWOT Analysis
  • 2.7.4 Qiagen Product and Services
  • 2.7.5 Qiagen Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.8 Siemens
  • 2.8.1 Siemens Details
  • 2.8.2 Siemens Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.8.3 Siemens SWOT Analysis
  • 2.8.4 Siemens Product and Services
  • 2.8.5 Siemens Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.9 Roche
  • 2.9.1 Roche Details
  • 2.9.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.9.3 Roche SWOT Analysis
  • 2.9.4 Roche Product and Services
  • 2.9.5 Roche Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.10 GenMark Diagnostics
  • 2.10.1 GenMark Diagnostics Details
  • 2.10.2 GenMark Diagnostics Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.10.3 GenMark Diagnostics SWOT Analysis
  • 2.10.4 GenMark Diagnostics Product and Services
  • 2.10.5 GenMark Diagnostics Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.11 Genomix Biotech
  • 2.11.1 Genomix Biotech Details
  • 2.11.2 Genomix Biotech Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.11.3 Genomix Biotech SWOT Analysis
  • 2.11.4 Genomix Biotech Product and Services
  • 2.11.5 Genomix Biotech Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)
• 2.12 BioTheranostics
  • 2.12.1 BioTheranostics Details
  • 2.12.2 BioTheranostics Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.12.3 BioTheranostics SWOT Analysis
  • 2.12.4 BioTheranostics Product and Services
  • 2.12.5 BioTheranostics Molecular Diagnostics in Infectious Disease Testing Revenue, Gross Margin and Market Share (2018-2019)

3 Market Competition, by Players

• 3.1 Global Molecular Diagnostics in Infectious Disease Testing Revenue and Share by Players (2015-2020)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Molecular Diagnostics in Infectious Disease Testing Players Market Share
  • 3.2.2 Top 10 Molecular Diagnostics in Infectious Disease Testing Players Market Share
• 3.3 Market Competition Trend

4 Market Size by Regions

• 4.1 Global Molecular Diagnostics in Infectious Disease Testing Revenue and Market Share by Regions
• 4.2 North America Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 4.3 Europe Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 4.4 Asia-Pacific Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 4.5 South America Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 4.6 Middle East & Africa Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)

5 North America Molecular Diagnostics in Infectious Disease Testing Revenue by Countries

• 5.1 North America Molecular Diagnostics in Infectious Disease Testing Revenue by Countries (2015-2020)
• 5.2 USA Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 5.3 Canada Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 5.4 Mexico Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)

6 Europe Molecular Diagnostics in Infectious Disease Testing Revenue by Countries

• 6.1 Europe Molecular Diagnostics in Infectious Disease Testing Revenue by Countries (2015-2020)
• 6.2 Germany Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 6.3 UK Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 6.4 France Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 6.5 Russia Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 6.6 Italy Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)

7 Asia-Pacific Molecular Diagnostics in Infectious Disease Testing Revenue by Countries

• 7.1 Asia-Pacific Molecular Diagnostics in Infectious Disease Testing Revenue by Countries (2015-2020)
• 7.2 China Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 7.3 Japan Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 7.4 Korea Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 7.5 India Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 7.6 Southeast Asia Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)

8 South America Molecular Diagnostics in Infectious Disease Testing Revenue by Countries

• 8.1 South America Molecular Diagnostics in Infectious Disease Testing Revenue by Countries (2015-2020)
• 8.2 Brazil Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 8.3 Argentina Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)

9 Middle East & Africa Revenue Molecular Diagnostics in Infectious Disease Testing by Countries

• 9.1 Middle East & Africa Molecular Diagnostics in Infectious Disease Testing Revenue by Countries (2015-2020)
• 9.2 Saudi Arabia Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 9.3 UAE Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 9.4 Egypt Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)
• 9.5 South Africa Molecular Diagnostics in Infectious Disease Testing Revenue and Growth Rate (2015-2020)

10 Market Size Segment by Type

• 10.1 Global Molecular Diagnostics in Infectious Disease Testing Revenue and Market Share by Type (2015-2020)
• 10.2 Global Molecular Diagnostics in Infectious Disease Testing Market Forecast by Type (2019-2024)
• 10.3 Polymerase Chain Reaction (PCR) Revenue Growth Rate (2015-2025)
• 10.4 Isothermal Nucleic Acid Amplification Technology (INAAT) Revenue Growth Rate (2015-2025)
• 10.5 Microarrays Revenue Growth Rate (2015-2025)
• 10.6 Next-Generation Sequencing (NGS) Revenue Growth Rate (2015-2025)
• 10.7 Hybridization Revenue Growth Rate (2015-2025)
• 10.8 Others Revenue Growth Rate (2015-2025)

11 Global Molecular Diagnostics in Infectious Disease Testing Market Segment by Application

• 11.1 Global Molecular Diagnostics in Infectious Disease Testing Revenue Market Share by Application (2015-2020)
• 11.2 Molecular Diagnostics in Infectious Disease Testing Market Forecast by Application (2019-2024)
• 11.3 Hospitals Revenue Growth (2015-2020)
• 11.4 Clinics Revenue Growth (2015-2020)
• 11.5 Academic Institutes Revenue Growth (2015-2020)
• 11.6 Laboratories Revenue Growth (2015-2020)
• 11.7 Others Revenue Growth (2015-2020)

12 Global Molecular Diagnostics in Infectious Disease Testing Market Size Forecast (2021-2025)

• 12.1 Global Molecular Diagnostics in Infectious Disease Testing Market Size Forecast (2021-2025)
• 12.2 Global Molecular Diagnostics in Infectious Disease Testing Market Forecast by Regions (2021-2025)
• 12.3 North America Molecular Diagnostics in Infectious Disease Testing Revenue Market Forecast (2021-2025)
• 12.4 Europe Molecular Diagnostics in Infectious Disease Testing Revenue Market Forecast (2021-2025)
• 12.5 Asia-Pacific Molecular Diagnostics in Infectious Disease Testing Revenue Market Forecast (2021-2025)
• 12.6 South America Molecular Diagnostics in Infectious Disease Testing Revenue Market Forecast (2021-2025)
• 12.7 Middle East & Africa Molecular Diagnostics in Infectious Disease Testing Revenue Market Forecast (2021-2025)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Data Source
• 14.3 Disclaimer